|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ: Panel members: Strategies for
subtypes - dealing with the diversity of breast cancer: Highlights
of the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferretti G, Felici A, Papaldo P, Fabi A
and Cognetti F: HER2/neu role in breast cancer: From a prognostic
foe to a predictive friend. Curr Opin Obstet Gynecol. 19:56–62.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thomas C and Gustafsson JA: The different
roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer.
11:597–608. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Diep CH, Daniel AR, Mauro LJ, Knutson TP
and Lange CA: Progesterone action in breast, uterine, and ovarian
cancers. J Mol Endocrinol. 54:R31–R53. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kuiper GG, Enmark E, Pelto-Huikko M,
Nilsson S and Gustafsson JA: Cloning of a novel receptor expressed
in rat prostate and ovary. Proc Natl Acad Sci USA. 93:5925–5930.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Haldosén LA, Zhao C and Dahlman-Wright K:
Estrogen receptor beta in breast cancer. Mol Cell Endocrinol.
382:665–672. 2014. View Article : Google Scholar
|
|
8
|
Leung YK, Lee MT, Lam HM, Tarapore P and
Ho SM: Estrogen receptor-beta and breast cancer: Translating
biology into clinical practice. Steroids. 77:727–737. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Biswas SK, Allavena P and Mantovani A:
Tumor-associated macrophages: Functional diversity, clinical
significance, and open questions. Semin Immunopathol. 35:585–600.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sica A and Mantovani A: Macrophage
plasticity and polarization: In vivo veritas. J Clin Invest.
122:787–795. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hao NB, Lü MH, Fan YH, Cao YL, Zhang ZR
and Yang SM: Macrophages in tumor microenvironments and the
progression of tumors. Clin Dev Immunol. 2012:9480982012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Allavena P, Sica A, Solinas G, Porta C and
Mantovani A: The inflammatory micro-environment in tumor
progression: The role of tumor-associated macrophages. Crit Rev
Oncol Hematol. 66:1–9. 2008. View Article : Google Scholar
|
|
16
|
Sica A, Schioppa T, Mantovani A and
Allavena P: Tumour-associated macrophages are a distinct M2
polarised population promoting tumour progression: Potential
targets of anti-cancer therapy. Eur J Cancer. 42:717–727. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sica A, Allavena P and Mantovani A: Cancer
related inflammation: The macrophage connection. Cancer Lett.
267:204–215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lau SK, Chu PG and Weiss LM: CD163: A
specific marker of macrophages in paraffin-embedded tissue samples.
Am J Clin Pathol. 122:794–801. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Holness CL and Simmons DL: Molecular
cloning of CD68, a human macrophage marker related to lysosomal
glycoproteins. Blood. 81:1607–1613. 1993.PubMed/NCBI
|
|
20
|
Matsumoto H, Koo SL, Dent R, Tan PH and
Iqbal J: Role of inflammatory infiltrates in triple negative breast
cancer. J Clin Pathol. 68:506–510. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Noh H, Hong S and Huang S: Role of
urokinase receptor in tumor progression and development.
Theranostics. 3:487–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu J, Jo M, Eastman BM, Gilder AS, Bui JD
and Gonias SL: uPAR induces expression of transforming growth
factor β and interleukin-4 in cancer cells to promote
tumor-permissive conditioning of macrophages. Am J Pathol.
184:3384–3393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lewis CE, Leek R, Harris A and McGee JO:
Cytokine regulation of angiogenesis in breast cancer: The role of
tumor-associated macrophages. J Leukoc Biol. 57:747–751.
1995.PubMed/NCBI
|
|
24
|
Leek RD, Hunt NC, Landers RJ, Lewis CE,
Royds JA and Harris AL: Macrophage infiltration is associated with
VEGF and EGFR expression in breast cancer. J Pathol. 190:430–436.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mahmoud SM, Lee AH, Paish EC, Macmillan
RD, Ellis IO and Green AR: Tumour-infiltrating macrophages and
clinical outcome in breast cancer. J Clin Pathol. 65:159–163. 2012.
View Article : Google Scholar
|
|
26
|
Mohammed ZM, Going JJ, Edwards J,
Elsberger B, Doughty JC and McMillan DC: The relationship between
components of tumour inflammatory cell infiltrate and
clinicopathological factors and survival in patients with primary
operable invasive ductal breast cancer. Br J Cancer. 107:864–873.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tiainen S, Tumelius R, Rilla K, Hämäläinen
K, Tammi M, Tammi R, Kosma VM, Oikari S and Auvinen P: High numbers
of macrophages, especially M2-like (CD163-positive), correlate with
hyaluronan accumulation and poor outcome in breast cancer.
Histopathology. 66:873–883. 2015. View Article : Google Scholar
|
|
28
|
Medrek C, Pontén F, Jirström K and
Leandersson K: The presence of tumor associated macrophages in
tumor stroma as a prognostic marker for breast cancer patients. BMC
Cancer. 12:3062012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gwak JM, Jang MH, Kim DI, Seo AN and Park
SY: Prognostic value of tumor-associated macrophages according to
histologic locations and hormone receptor status in breast cancer.
PLoS One. 10:e01257282015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Engström A, Erlandsson A, Delbro D and
Wijkander J: Conditioned media from macrophages of M1, but not M2
phenotype, inhibit the proliferation of the colon cancer cell lines
HT-29 and CACO-2. Int J Oncol. 44:385–392. 2014.
|
|
31
|
Ruijter JM, Ramakers C, Hoogaars WM,
Karlen Y, Bakker O, van den Hoff MJ and Moorman AF: Amplification
efficiency: Linking baseline and bias in the analysis of
quantitative PCR data. Nucleic Acids Res. 37:e452009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hedbrant A, Wijkander J, Seidal T, Delbro
D and Erlandsson A: Macrophages of M1 phenotype have properties
that influence lung cancer cell progression. Tumour Biol.
36:8715–8725. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Duffy MJ, O'Donovan N, McDermott E and
Crown J: Validated biomarkers: The key to precision treatment in
patients with breast cancer. Breast. 29:192–201. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao S, Ma W, Zhang M, Tang D, Shi Q, Xu
S, Zhang X, Liu Y, Song Y, Liu L, et al: High expression of CD147
and MMP-9 is correlated with poor prognosis of triple-negative
breast cancer (TNBC) patients. Med Oncol. 30:3352013. View Article : Google Scholar
|
|
35
|
Dai X, Xiang L, Li T and Bai Z: Cancer
hallmarks, biomarkers and breast cancer molecular subtypes. J
Cancer. 7:1281–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dunnwald LK, Rossing MA and Li CI: Hormone
receptor status, tumor characteristics, and prognosis: A
prospective cohort of breast cancer patients. Breast Cancer Res.
9:R62007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Stossi F, Madak-Erdoğan Z and
Katzenellenbogen BS: Macrophage-elicited loss of estrogen
receptor-α in breast cancer cells via involvement of MAPK and c-Jun
at the ESR1 genomic locus. Oncogene. 31:1825–1834. 2012. View Article : Google Scholar
|
|
38
|
Chavey C, Bibeau F, Gourgou-Bourgade S,
Burlinchon S, Boissière F, Laune D, Roques S and Lazennec G:
Oestrogen receptor negative breast cancers exhibit high cytokine
content. Breast Cancer Res. 9:R152007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee SH and Nam HS: TNF alpha-induced
down-regulation of estrogen receptor alpha in MCF-7 breast cancer
cells. Mol Cells. 26:285–290. 2008.PubMed/NCBI
|
|
40
|
Bhat-Nakshatri P, Campbell RA, Patel NM,
Newton TR, King AJ, Marshall MS, Ali S and Nakshatri H: Tumour
necrosis factor and PI3-kinase control oestrogen receptor alpha
protein level and its transrepression function. Br J Cancer.
90:853–859. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Oida K, Matsuda A, Jung K, Xia Y, Jang H,
Amagai Y, Ahn G, Nishikawa S, Ishizaka S, Jensen-Jarolim E, et al:
Nuclear factor-ĸB plays a critical role in both intrinsic and
acquired resistance against endocrine therapy in human breast
cancer cells. Sci Rep. 4:40572014. View Article : Google Scholar
|
|
42
|
Freund A, Chauveau C, Brouillet JP, Lucas
A, Lacroix M, Licznar A, Vignon F and Lazennec G: IL-8 expression
and its possible relationship with estrogen-receptor-negative
status of breast cancer cells. Oncogene. 22:256–265. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
D'Anello L, Sansone P, Storci G, Mitrugno
V, D'Uva G, Chieco P and Bonafé M: Epigenetic control of the
basal-like gene expression profile via Interleukin-6 in breast
cancer cells. Mol Cancer. 9:3002010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hedbrant A, Erlandsson A, Delbro D and
Wijkander J: Conditioned media from human macrophages of M1
phenotype attenuate the cytotoxic effect of 5-fluorouracil on the
HT-29 colon cancer cell line. Int J Oncol. 46:37–46. 2015.
|
